MRI Interventions and Monteris Medical have partnered to develop next generation head fixation frames for use in laser ablation neurosurgery.
Under the terms of the collaborative co-development agreement, MRI Interventions will receive license to intellectual property (IP) and technical development from Monteris.
A joint product will be developed including MRI Interventions’ design concepts and IP.
MRI Interventions will also support Monteris in FDA filings. The two companies will market and sell the new head fixation frame to existing and future customers.
The product will be compatible with AtamA Patient Transfer and Head Stabilization System.
As part of its four-pillar growth strategy, MRI Interventions partners with other device, biologics and drug companies to provide the best products and workflow possible to allow life-saving and life-altering therapies.
MRI Interventions portfolio manager Chris Osswald said: “While precision, accuracy and quality are essential to delivering the best possible outcomes for our patients, efficiency, procedure time and cost is crucial for our hospital customers.
“By partnering with Monteris on this next-generation head fixation frame project, we believe we can improve the overall patient experience, as well as workflow and time of procedure, helping hospitals to make the most of their time both in the operating room and in the MRI suite.
“In this case, two companies are better than one, and together we believe we can make a better product than we could individually.”
MRI is in the development of new platforms for conducting minimally invasive surgical procedures in the brain.
In May this year, the company partnered with Voyager Therapeutics, a company focused the development of gene-therapy for treating neurological diseases.
The partnership included service and clinical case support of MRI’s ClearPoint and SmartFlow products employed in Voyager’s planned Phase 2-3 pivotal program of its gene therapy, VY-AADC, for Parkinson’s disease.
The two companies had also agreed to jointly develop new minimally invasive neurosurgical devices using intra-procedural, or real-time, magnetic resonance imaging (MRI) guidance, including joint development of new hardware, software and cannulas to support delivery of certain Voyager gene therapy programs.